UAE IVF Drugs And Food Supplements Market Analysis & Forecast: 2026-2033
The UAE IVF drugs and food supplements market is estimated to be valued at USD 26.4 Mn in 2026 and expected to reach USD 41.3 Mn by 2033, witnessing a CAGR of 6.6% over the forecast period (2026-2033).
IVF is a type of assisted reproduction technology in which a woman's reproductive system is artificially encouraged to create oocytes, which are then harvested, fertilized in a lab, and placed in the uterus. Due to complications, IVF specialist provides drugs and food supplements to patients undergoing IVF treatment.
IVF treatment procedure includes ovarian stimulation, ovulation induction, oocyte harvest, sperm fertilization, and transport of the fertilized oocytes for implantation. There are various drugs which are commonly used for IVF treatment such as Clomiphene used for inducing ovulation and also injectables available for IVF treatment which includes gonadotropin-releasing hormone (GnRH) and follicle-stimulating hormone (FSH), that produce progesterone to maintain the pregnancy.
GonGnRH antagonist inhibit of a premature LH rise and also there are various food supplements which are commonly provided to the patients under IVF treatment such as Coenzyme Q10 (CoQ10) to improve egg quality, sperm quality, and pregnancy rates and DHEA used as an adjuvant for in vitro fertilization (IVF) cycles in poor ovarian responders.
|
Current Event |
Description and its Impact |
|
UAE Healthcare Vision 2071 and Fertility Treatment Expansion |
|
|
Technological Advancements in Personalized Fertility Medicine |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
|
Cost Component |
Price Range (USD) |
Notes |
|
IVF Cycle (procedure only) |
8,000 – 12,000 |
Includes consultation, egg retrieval, fertilization, embryo transfer |
|
IVF Drugs (Clomiphene, hCG, FSH, hMG, GnRH agonists/antagonists) |
2,000 – 4,000 |
Essential for ovarian stimulation and cycle regulation |
|
Food Supplements (nutritional support for egg/sperm quality) |
500 – 1,500 |
Vitamins, antioxidants, hormonal balance supplements |
|
Total (without bundle) |
10,500 – 17,500 |
Separate purchase of drugs and supplements |
|
Total (with bundled package) |
9,500 – 14,000 |
Clinics/pharmacies offer combined IVF + drugs + supplements |
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of product type, the drugs segment is expected to lead the market with 60% of the share in 2026. Injectable hormones, such as hCG, FSH, hMG, and GnRH analogs, will be the most popular because they are necessary for starting ovulation, stimulating follicles, and controlling the cycle. Clomiphene citrate is still a common prescription, but GnRH agonists and antagonists give high precise hormonal control in advanced IVF protocols.
For example, in February 2026, Fakih IVF opens a new branch in Khalifa City, Abu Dhabi, which makes the region's fertility healthcare system better. The expansion makes it easier for patients to get advanced reproductive treatments, encourages medical tourism, and indirectly increases the demand for IVF drugs and food supplements. This strengthens Abu Dhabi's position as a major center for reproductive medicine in the UAE.
In terms of distribution channel, the hospital pharmacies segment is expected to hold 52.7% share of the market in 2026, because patients rely on specialized fertility centers to get their prescribed IVF drugs directly. Centralized dispensing makes sure that treatments are correct, follow the rules, and are overseen by doctors. This makes them even more dominant than retail and online channels in the UAE reproductive healthcare market.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 26.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.6% | 2033 Value Projection: | USD 41.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Shinelife, Adorefem, LG Chem, Adorshea, Biofield Pharma, Medibyte, Mestra Pharma, Dr. D Pharma, Abbott, Zydus, Takeda Pharmaceutical Company Limited, Merck KGaA, and Ferring B.V. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Infertility in the UAE is becoming increasingly interconnected to lifestyle factors like stress, obesity, and delayed childbearing. These problems are driving couples seek out more advanced reproductive solutions, especially IVF. As a result of this, the UAE IVF Drugs and Food Supplements Market growth accelerates, with more people wanting medicines like Clomiphene, hCG, FSH, hMG, and GnRH agonists/antagonists. Along with these drugs, people are also taking nutritional supplements to improve their chances of getting pregnant, expanding the market.
Public campaigns and private fertility clinics in the UAE are working hard to make IVF treatments more common, which will help break down the stigma around them and encourage couples to explore assisted reproductive technologies. As a result of this change in culture, people are more willing to use hormone therapies and nutritional supplements together to improve their chances of success. Consequently, the UAE IVF drugs and food supplements market demand is growing as more couples choose holistic methods of fertility care. More people are becoming aware of advanced reproductive healthcare solutions, which is not only increasing adoption but also building trust in them.
Dubai and Abu Dhabi are trying to become global fertility centers that draw patients from the GCC, Africa, and Europe. The UAE is a popular place for IVF treatments because it has advanced healthcare infrastructure, skilled specialists, and low prices. Clinics and drug companies can take advantage of this by offering affordable IVF packages that come with food supplements. This will improve treatment outcomes and make patients happier. The UAE IVF Drugs and Food Supplements market forecast show that this trend is a significant opportunity, which will drive international demand and long-term growth.
For instance, in June 2025, the $450 million purchase of ART Fertility Clinics by KKR-backed IVI highlights that Abu Dhabi and Dubai are becoming more important in reproductive health care. The news is mostly about companies growing, but it also has something to do with IVF drugs and food supplements. A greater number of patients will mean more demand for hormone therapies and nutritional support.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
